​

Castle Biosciences Ownership | Who Owns Castle Biosciences?

OverviewForecastRevenueFinancialsChartTranscripts

Castle Biosciences Ownership Summary

Castle Biosciences is owned by 91.74% institutional investors, 2.77% insiders, and 5.49% retail investors. Blackrock is the largest institutional shareholder, holding 11.08% of CSTL shares. Bellevue Healthcare Ord is the top mutual fund, with 4.32% of its assets in Castle Biosciences shares.

CSTL Ownership Benchmark

TypeName% Inst% Insiders% Retail
StockCastle Biosciences91.74%2.77%5.49%
SectorHealthcare Stocks 42.50%10.81%46.69%
IndustryDiagnostics & Research Stocks45.39%10.59%44.03%

Institutional Shareholders

Top Institutional Shareholders by Total Shares

HolderShares% HoldingValue
Blackrock3.04M11.08%$66.29M
Blackrock funding, inc. /de3.19M11.03%$72.63M
Vanguard group2.17M7.51%$49.46M
Principal financial group1.79M6.21%$40.86M
Portolan capital management1.52M5.24%$34.50M
Dimensional fund advisors lp1.47M5.10%$33.56M
Nuveen957.08K3.31%$21.79M
Braidwell lp822.74K2.85%$18.73M
State street724.08K2.50%$16.49M
Aigh capital management707.29K2.45%$16.10M

Top Institutional Shareholders by % of Total Assets

HolderShares% AssetsValue
Aigh capital management707.29K4.54%$16.10M
Birchview capital, lp110.60K1.90%$2.52M
Portolan capital management1.52M1.87%$34.50M
Parkman healthcare partners475.57K1.13%$10.83M
Perkins capital management28.14K0.56%$640.86K
Braidwell lp822.74K0.56%$18.73M
Palisade capital management, lp638.66K0.40%$14.54M
Green alpha advisors9.54K0.21%$217.18K
Summit partners public asset management400.00K0.19%$9.11M
Alpha dna investment management15.17K0.15%$404.39K

Top Buyers

HolderShares% AssetsChange
Aigh capital management707.29K4.54%707.29K
Blackrock3.04M0.00%449.29K
Millennium management548.81K0.01%408.27K
Summit partners public asset management400.00K0.19%400.00K
Point72 asset management336.96K0.01%336.96K

Top Sellers

HolderShares% AssetsChange
Park west asset management---556.49K
Wellington management group llp---407.21K
Wasatch advisors lp669.12K0.08%-380.65K
Bellevue group---301.10K
Soleus capital management---252.92K

New Positions

HolderShares% AssetsChangeValue
Aigh capital management707.29K4.54%707.29K$16.10M
Summit partners public asset management400.00K0.19%400.00K$9.11M
D. e. shaw90.56K0.00%90.56K$2.41M
Summittx capital45.00K0.04%45.00K$1.02M
Panagora asset management21.40K0.00%21.40K$487.23K

Sold Out

HolderChange
Nelson, van denburg & campbell wealth management group-1.00
Twin peaks wealth advisors-1.00
National bank of canada /fi/-1.00
Stephens consulting-2.00
Colonial trust advisors-6.00

Institutional Ownership Trends

DateHoldingsChange %SharesChange %OwnershipChange %Increased PositionChange %Decreased PositionChange %
Sep 30, 202517112.50%26,525,363-0.04%911.09%939.41%5420.00%
Jun 30, 2025151-17.03%26,530,4542.55%911.12%85-19.81%44-18.52%
Mar 31, 2025178-13.17%25,557,223-3.26%890.99%105-2.78%53-19.70%
Dec 31, 20242023.59%26,322,0332.20%941.10%106-11.67%6538.30%
Sep 30, 202419518.90%25,754,3952.29%921.12%11938.37%48-4.00%

Top Mutual Funds Shareholders

HolderShares% HoldingChange
Bellevue Healthcare Ord1.20M4.32%1.20M
Vanguard US Total Market Shares ETF829.40K2.96%-
Principal SmallCap R5829.94K2.86%78.59K
Vanguard Total Stock Mkt Idx Inv826.46K2.85%-18.32K
Principal U.S. Small Cap Equity781.42K2.71%159.12K
Strategic Advisers U.S. Total Stock{mg}693.06K2.47%-
Wasatch Small Cap Growth Investor675.19K2.41%-14.34K
Strategic Advisers Small-Mid Cap665.91K2.40%62.85K
iShares Russell 2000 ETF691.79K2.38%-
Wasatch Ultra Growth627.21K2.17%33.31K

Recent Insider Transactions

DateNameRoleActivityValue
Dec 02, 2025MAETZOLD DEREK J Pres. & Chief Exec. OfficerSell$105.06K
Nov 26, 2025MAETZOLD DEREK J Pres. & Chief Exec. OfficerSell$170.70K
Nov 25, 2025MAETZOLD DEREK J Pres. & Chief Exec. OfficerSell$204.85K
Nov 20, 2025Juvenal Tobin W Chief Commercial OfficerSell$166.98K
Nov 18, 2025MAETZOLD DEREK J Pres. & Chief Exec. OfficerSell$91.11K

Insider Transactions Trends

DateBuySell
2025 Q4-17
2025 Q3-7
2025 Q2-20
2025 Q1-61
2024 Q4-64

CSTL Ownership FAQ

Who Owns Castle Biosciences?

Castle Biosciences shareholders are primarily institutional investors at 91.74%, followed by 2.77% insiders and 5.49% retail investors. The average institutional ownership in Castle Biosciences's industry, Diagnostics & Research Stocks, is 45.39%, which Castle Biosciences exceeds.

Who owns the most shares of Castle Biosciences?

Castle Biosciences’s largest shareholders are Blackrock (3.04M shares, 11.08%), Blackrock funding, inc. /de (3.19M shares, 11.03%), and Vanguard group (2.17M shares, 7.51%). Together, they hold 29.62% of Castle Biosciences’s total shares outstanding.

Does Blackrock own Castle Biosciences?

Yes, BlackRock owns 11.08% of Castle Biosciences, totaling 3.04M shares as of Jun 2024. This represents 0.00% of BlackRock's total assets, with a market value of 66.29M$. In the last quarter, BlackRock increased its holdings by 449.29K shares, a 17.31% change.

Who is Castle Biosciences’s biggest shareholder by percentage of total assets invested?

Aigh capital management is Castle Biosciences’s biggest shareholder by percentage of total assets invested, with 4.54% of its assets in 707.29K Castle Biosciences shares, valued at 16.1M$.

Who is the top mutual fund holder of Castle Biosciences shares?

Bellevue Healthcare Ord is the top mutual fund holder of Castle Biosciences shares, with 4.32% of its total shares outstanding invested in 1.2M Castle Biosciences shares.

Try Tickergate Pro Free

Customize Everything. 100% Flexibility. Fast and Easy to Use (No code or Excel Needed)

  • Customize your own personal stocks lists, views and charts

  • Choose from hundreds of fields, up to 15 years of history

  • Conduct deep comparison analysis

  • Discover trending investment themes

  • Find your next best investment

  • Research stocks using tools